"10.1371_journal.pone.0045291","plos one","2012-09-28T00:00:00Z","Itaru Anraku; Reena Rajasuriar; Caroline Dobbin; Richard Brown; Sharon R Lewin; Andreas Suhrbier","Queensland Institute of Medical Research, Brisbane, Queensland, Australia; Department of Infectious Diseases, Alfred Hospital, Melbourne, Victoria, Australia; Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia; CBio Ltd., Brisbane, Queensland, Australia; Monash University, Melbourne, Victoria, Australia; Centre for Virology, Burnet Institute, Melbourne, Victoria, Australia; School of Biomolecular and Physical Sciences, Griffith University, Brisbane, Queensland, Australia","Conceived and designed the experiments: RR CD RB SL AS. Performed the experiments: IA RR CD. Analyzed the data: IA AS. Contributed reagents/materials/analysis tools: CD RB SL RR. Wrote the paper: AS. Manuscript review: IA RR CD SL.","CD is employed by CBio Ltd. RB was at the time of the study (but is no longer) an employee of CBio. AS has been a consultant for CBio, and undertakes contract research for CBio. CBio Ltd. is developing a new immunomodulatory agent based on Hsp10, and AS, RB, CD are inventors on patents pertaining to the use of Cpn10 as an immunomodulatory agent for treating inflammatory diseases. The authors found no association between clinical parameters and Hsp10 levels in this study. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2012","09","Itaru Anraku","IA",6,TRUE,5,3,2,1,TRUE,TRUE,FALSE,0,NA,FALSE
